Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD
This long-term follow-up study (n=24) applied qualitative interviews, an interpretative phenomenological analysis, and quantitative questionnaires to assess the perceived benefits of MDMA-assisted psychotherapy, following a two-year period after the completion of a Phase II clinical trial. Participant depictions of their experience before, during, and in the year after the treatment provide a rich context that demonstrates how MDMA-assisted psychotherapy can impact important areas of functioning as well as the overall quality of life, regardless of changes to PTSD symptoms.
Authors
- Barone, W.
- Beck, J.
- Mitsunaga-Whitten, M.
Published
Abstract
Introduction
We present select findings from a long-term follow-up qualitative study of MDMA-assisted psychotherapy for veterans, firefighters, and police officers suffering from chronic, treatment-resistant PTSD.
Methods
Semi-structured qualitative interviews were conducted at participants’ one-year follow-up after a recently completed phase 2 clinical trial. Available interviews from 19 of 24 participants were analyzed. This qualitative analysis sought to complement, clarify, and expand upon the quantitative findings obtained from the Clinician Administered PTSD Scale (CAPS-IV) and supported by the Long-Term Follow-Up (LTFU) Questionnaire. Pertinent data from interview transcripts were coded and analyzed using an interpretative phenomenological analysis (IPA) methodological framework. We explore prominent thematic elements from participant accounts to better understand the outcomes experienced in this trial.
Results
All participants reported experiencing lasting personal benefits and enhanced quality of life that extend beyond quantifiable symptom reduction.
Discussion
We explore a range of treatment benefits beyond symptom reduction to highlight the utility of qualitative investigations of the process and effects of MDMA-assisted psychotherapy. Limitations and challenges encountered in conducting this study are discussed along with recommendations for improved qualitative research protocols in future clinical trials.
Research Summary of 'Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD'
Introduction
Post-traumatic stress disorder (PTSD) is a significant public‑health problem among military veterans and first responders, producing occupational, relational and psychological dysfunction, reduced quality of life, and increased suicide risk. While multiple pharmacological and psychotherapeutic treatments exist, a substantial group remains treatment‑resistant. Multidisciplinary Association for Psychedelic Studies (MAPS)-sponsored Phase II trials have investigated MDMA-assisted psychotherapy in such populations, typically using the Clinician Administered PTSD Scale (CAPS‑IV) as the primary quantitative efficacy measure. The authors argue that CAPS‑IV captures frequency and intensity of core PTSD symptoms but does not encompass broader quality‑of‑life changes or nuanced experiential outcomes that may follow this intervention. Barone and colleagues report a long‑term qualitative follow‑up of participants from a Phase II MDMA-assisted psychotherapy trial for military veterans and first responders. Their aim was to complement and expand upon CAPS‑IV and Long‑Term Follow‑Up (LTFU) questionnaire results by identifying thematic elements of participants’ experiences before, during and after treatment, thereby illuminating perceived benefits that lie beyond symptom reduction.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- APA Citation
Barone, W., Beck, J., Mitsunaga-Whitten, M., & Perl, P. (2019). Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. Journal of Psychoactive Drugs, 51(2), 199-208. https://doi.org/10.1080/02791072.2019.1580805
References (11)
Papers cited by this study that are also in Blossom
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Kirchner, K. · Journal of Psychopharmacology (2014)
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A. et al. · Lancet Psychiatry (2018)
Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2012)
Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Ot'alora G, M., Grigsby, J., Poulter, B. et al. · Journal of Psychopharmacology (2018)
Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)
Show all 11 referencesShow fewer
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Cited By (14)
Papers in Blossom that reference this study
Agin-Liebes, G. I., Zeifman, R. J., Mitchell, J. · European Journal of Psychotraumatology (2025)
Sarmanlu, M., Kuypers, K. P. C., Vizeli, P. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023)
Godes, M., Lucas, J., Vermetten, E. · Frontiers in Psychiatry (2023)
Kangaslampi, S., Zijlmans, J. · European Child and Adolescent Psychiatry (2023)
Barone, W., Mitsunaga-Whitten, M., Blaustein, L. O. et al. · Frontiers in Psychiatry (2022)
Breeksema, J. J., Kuin, B. W., Kamphuis, J. et al. · Journal of Psychopharmacology (2022)
Ching, T. H., Williams, M. T., Wang, J. B. et al. · Journal of Psychopharmacology (2022)
Soares, C. M., Leite, A., Pinto, M. · Journal of Psychoactive Drugs (2022)
Ching, T. H., Williams, M. T., Reed, S. et al. · Journal of Humanistic Psychology (2022)
Luoma, J. B., Lear, M. K. · Frontiers in Psychiatry (2021)
Show all 14 papersShow fewer
Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)
Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · CNS Drugs (2020)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.